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Recent studies indicate that patients with chronic graft-versus-host disease (GVHD) are 
not expected to show positivity for anti-mitochondrial antibody (AMA), which is a specific 
disease marker for primary biliary cirrhosis (PBC). A differential diagnosis between PBC 
and hepatic involvement of GVHD based on clinical manifestations and pathologic study 
is difficult because both diseases show similar results. Therefore, the presence of AMA 
may be important for distinguishing each disease. Here, we report a case of hepatic 
involvement of chronic GVHD with positive AMA, in which the pathologic findings and 
initial presentation of clinical findings were compatible with both PBC and chronic GVHD.
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INTRODUCTION
Primary biliary cirrhosis (PBC) and hepatic involvement 
in chronic graft-versus-host disease (GVHD) following 
hematopoietic stem cell transplantation (HSCT) have many 
similarities. Both show similar clinical manifestations, and 
laboratory and pathologic findings. Furthermore, in previous 
studies, anti-mitochondrial antibodies (AMAs) were detected 
in patients with chronic GVHD even though AMA is a very 
specific disease marker for PBC [1-4]. Recently, however, 
several studies have shown negative AMA in the serum 
of chronic GVHD patients following HSCT, and it has been 
thought that the previously reported results may have been 
false positives, with AMA being a disease marker for PBC 
only [5]. Here, we present a case of AMA-positive hepatic 
involvement in chronic GVHD following HSCT, showing 
pathologic compatibility with PBC.
CASE REPORT
A 28-year-old woman presented with fever and gener-
alized myalgia in July 2008. She was diagnosed as having 
acute myeloid leukemia (AML) with t(6;9). She was treated 
with induction chemotherapy followed by HLA fully 
matched peripheral blood stem cell transplantation from her 
brother in December 2008.
Her liver function test was normal before treatment for 
AML, and there were no symptoms suggesting liver disease 
or autoimmune disorder. She did not have a history of liver 
disease, skin disorder, or autoimmune disorder. The viral 
marker tests against hepatitis were negative.
Six months after transplantation, in June 2009, she devel-
oped a skin rash on her extremities, together with anorexia 
and nausea. Skin biopsy was performed on suspicion of skin 
involvement in chronic GVHD. Her skin showed lym-
phocyte-dominated superficial perivascular dermatitis with 
exocytosis of the epidermis, and she was diagnosed as having 
skin involvement in chronic GVHD. Of her laboratory 
findings, hemoglobin was 9.8 g/dL, white blood cell count Korean J Hematol 2011;46:200-2.
AMA in hepatic involvement of GVHD 201
Fig. 1. Liver biopsy reveals mild biliary epithelial damage of portal tract, 
lymphocytic infiltraion and mild peacemeal necrosis.
was 5.2×10
9/L (neutrophils 38.4%, lymphocytes 41.2%, 
monocytes 12.2%, eosinophils 7.8%), aspartate aminotrans-
ferase (AST) was 35 IU/L, alanine aminotransferase (ALT) 
was 91 IU/L, alkaline phosphatase (ALP) was 540 IU/L, and 
total bilirubin was 0.4 mg/dL, with direct bilirubin 0.2 mg/dL. 
There was no definite cause to explain the abnormal result 
of the liver function test except hepatic involvement in 
chronic GVHD. She had been treated with cyclosporine, 
and the prescription was changed to prednisolone (PRS) 
15 mg/day, FK506 2 mg/day, and ursodeoxycholic acid 
(UDCA), 600 mg/day. Immunosuppressive agents were 
tapered slowly owing to chronic GVHD. She continued 
taking immunosuppressive agents until March 18, 2010.
On July 1, 2010, 4 months after cessation of immuno-
suppressive agents, she presented with fatigue, generalized 
pruritus, and arthralgia on knees, elbows, and wrists. On 
physical examination, both her knees were swollen with 
no heat or redness, and the skin on her extremities was 
covered with multiple scratches. Blood investigation showed 
hemoglobin of 13.5 g/dL, white blood cell count of 16.0×10
9/L 
[neutrophils 36%, lymphocytes 23.3%, monocytes 10.8%, 
eosinophils 29.3% (6.08×10
9/L)], AST of 50 IU/L, ALT of 
47 IU/L, ALP of 472 IU/L, and total bilirubin of 0.5 mg/dL 
with direct bilirubin of 0.2 mg/dL.
Autoantibodies were tested to investigate autoimmune 
disease, and the results showed positivity for antinuclear 
antibody (ANA) and AMA subtype M2. Indirect immuno-
fluorescence (IIF) using both rat tissue and Hep2 cells, and 
an immunoblot assay (IBL) were used for detecting AMA, 
and the results were consistent on repeated testing. Other 
autoantibodies against nRNP/Sm, Sm, SS-A, Ro-52, SSB, 
Scl-70, PM-Scl, Jo-1, CENP-B, PCNA, dsDNA, nucleosome, 
histone, and ribosomal P protein were negative.
Ultrasonography of her abdomen was normal, and a liver 
biopsy was performed. The liver specimen showed chronic 
hepatitis accompanied by mild lobular activity with lipo-
granuloma, cholestasis, pseudo-rosette formation, and 
ballooning degeneration. Mild porto-periportal activity with 
biliary epithelial damage was also observed, and bile ductule 
proliferation with occasional plasma cell infiltration was seen 
(Fig. 1). Portal fibrosis was present and all the findings were 
consistent with PBC. However, clinically she was considered 
to have hepatic involvement, joint manifestation, and skin 
involvement in chronic GVHD. It was decided that she 
should be treated with immune suppression therapy and 
a high dose of UDCA. PRS 20 mg/day, FK506 1 mg/day, 
and UDCA 900 mg/day were prescribed. Celecoxib 400 
mg/day was also used to manage arthralgia.
On August 5, 2010, her blood count showed hemoglobin 
of 13.9 g/dL, white blood cell count of 14.8×10
9/L (neutrophils 
47.4%, lymphocytes 40.1%, monocytes 11.3%, eosinophils 
0.8%), AST of 17 IU/L, ALT of 19 IU/L, ALP of 279 IU/L, 
and total bilirubin of 0.5 mg/L. Her arthralgia, eosinophilia, 
and hepatic dysfunction improved.
On February 10, 2011, FK506 was suspended, but she 
complained of aggravated arthralgia after 6 weeks. FK506 
was readministered at 1 mg/day, which was the previous 
maintenance dose, and her arthralgia soon improved.
On March 31, 2011, AMA was again checked using IIF 
and IBL and was again positive, but her symptoms improved 
and blood investigations did not show eosinophilia or 
abnormal liver function, with hemoglobin of 14.5 g/dL, white 
blood cell count 13.1×10
9/L (neutrophils 41.7%, lymphocytes 
40.7%, monocytes 13.2%, eosinophils 3.6%), AST of 28 IU/L, 
ALT of 19 IU/L, ALP of 289 IU/L, total bilirubin of 0.5 
mg/dL, and direct bilirubin of 0.3 mg/dL.
To date, she has been taking PRS 5 mg, FK506 1 mg, 
and UDCA 900 mg.
DISCUSSION
Although the mechanism of chronic GVHD is obscure, 
there are similarities between chronic GVHD and auto-
immune disease. In the present case, the patient complained 
of fatigue, pruritus, and arthralgia, which are present in 
PBC. Although more than half of PBC patients are 
asymptomatic, fatigue is present in 80% and pruritus is 
present in 20-70% of symptomatic patients [6]. In addition, 
inflammatory arthropathy is present in 4-50% of PBC 
patients [7]. Because differential diagnosis of both diseases 
from clinical symptoms and pathologic findings is difficult, 
AMA is an important laboratory finding to support PBC 
diagnosis.
Autoantibodies are frequently detected in the serum of 
chronic GVHD patients with or without autoimmune mani-
festations. Together with other autoantibodies, such as ANA, 
AMA has also been detected in the serum of chronic GVHD 
patients, and a positivity rate of 4-81% has been reported 
[1-4].
However, more recently, results showing negativity in 
the AMA test have been reported, and positive reports are Korean J Hematol 2011;46:200-2.
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thought to have been false positives [8, 9]. Quaranta et al. 
checked AMA in the serum of 89 chronic GVHD patients 
by IIF, IBL, and enzyme-linked immunosorbent assay 
(ELISA) but no patient was positive for AMA [8]. They 
explained the cause of the negative AMA result, which was 
different from previous reports, as follows. First, combination 
treatment with corticosteroids, cyclosporine, thalidomide, 
and FK506 had been used recently, although there was no 
data reporting any correlation between antibody production 
and such medications. Second, mismatched proteins against 
mitochondrial antigens were demonstrated in PBC patients 
in the study by Siegert et al. [2], which showed the highest 
frequency of AMA. Siegert et al. reported the molecular 
masses of matched proteins to be 63/60 and 22 kDa, whereas 
Quaranta et al. [8] reported molecular masses of 74, 56, 
and 52 kDa.
Approximately 10-15% of PBC patients are negative for 
AMA, and laboratory tests have placed emphasis on detecting 
AMA in AMA-negative PBC patients. Many centers use IIF 
for detecting AMA; however, newly developed methods, 
including those using ELISA, have been used. The sensitivity 
of ELISA is superior to that of IIF, although, with regard 
to its specificity, IIF is not inferior to ELISA [10, 11].
In our case, the patient was tested for AMA using IIF 
and IBL. The results showed positivity on repeated tests 
and tests over time. The presence of AMA in her serum 
was therefore considered to be confirmed. Autoantibody 
tests, including AMA, were not performed at initial diagnosis 
of leukemia. Autoantibody testing is not routine in leukemia, 
and she did not have any symptoms to cause us to suspect 
autoimmune disorder. Furthermore, her liver function tests 
were within normal limits and she did not have any 
symptoms of arthropathy or dermopathy before transplan-
tation. Because this patient was not part of a prospective 
study, there was no reason to evaluate the presence of auto-
antibodies.
The treatments for chronic GVHD and PBC are different. 
Most chronic GVHDs are treated with immunosuppressive 
agents such as glucocorticoids, FK506, and cyclosporine, 
whereas PBCs are commonly treated with UDCA. However, 
corticosteroids, colchicine, and immunosuppressive agents 
such as cyclosporine, can also be used for PBCs, since they 
are thought to be adjuvants [12]. Our patient’s symptoms 
responded to immune suppression therapy, but the treatment 
also included a high dose of UDCA. It is difficult to judge 
whether PBC responded to UDCA or chronic GVHD 
responded to immune suppression therapy. However, on 
balance, we considered that she had hepatic involvement 
of chronic GVHD, because she was young and had developed 
these problems following HSCT.
Many autoantibodies have been reported in patients with 
chronic GVHD. Detecting the presence of AMA is more 
important than for other autoantibodies, because PBC shows 
very similar symptoms to hepatic involvement of chronic 
GVHD, making differential diagnosis an important aspect 
when choosing treatment modality. In this case, it was 
difficult to decide whether to continue the high dose of 
UDCA treatment. Therefore, confirming the possibility of 
the presence of AMA in the serum of chronic GVHD patients 
was important. Recent reports seem to consider that AMA 
would not be detected in the serum of chronic GVHD patients 
[1, 8]. However, further studies focusing on AMA using 
various detection modalities are required, because previous 
studies in which AMA has been detected in GVHD patients 
certainly exist. This case is significant in this regard.
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